Queuosine, a lesser-known but vital vitamin-like molecule first identified in the 1970s, is critical for optimal human health. Unlike many essential nutrients, humans lack the metabolic pathways to synthesize queuosine internally. Instead, queuosine is acquired exclusively through dietary sources and the metabolic activities of gut microbiota. Despite its significance, the biochemical mechanisms governing its absorption at the cellular level remained a mystery until this recent breakthrough.

Central to this discovery is the gene SLC35F2, previously recognized in oncology circles as an oncogene and associated with the transport of cancer drugs and viral particles. However, its physiological role within healthy cells was poorly understood. The research team has now established that SLC35F2 functions with remarkable specificity to ferry queuosine and its precursor queuine into cells, enabling their incorporation into transfer RNA (tRNA) molecules that decode genetic information. This function is fundamental to protein synthesis and, by extension, to the regulation of myriad cellular activities.

Transfer RNAs are essential adaptors in the translation process, interpreting messenger RNA sequences to assemble amino acids into functional proteins. Queuosine’s modification of tRNA molecules fine-tunes this decoding process, enhancing fidelity and efficiency. Such modifications influence cellular responses from brain plasticity and memory formation to metabolic regulation and cancer suppression, revealing queuosine’s pervasive impact on human health at a molecular level.

Valérie de Crécy-Lagard, a distinguished professor of microbiology and cell science at the University of Florida and co-lead of the study, highlighted the significance of identifying the queuosine transporter. She remarked that despite over three decades of speculation, the transporter gene had evaded detection, underscoring the challenge posed by its subtle but vital biological role. “Finding SLC35F2 as the gatekeeper for queuosine ushers in a transformative era in understanding the interplay between diet, the microbiome, and gene translation,” de Crécy-Lagard explained.

The multidisciplinary team’s approach combined cutting-edge genomic screening techniques with functional assays to pinpoint the transporter’s identity. Their work went beyond model organisms, rigorously validating SLC35F2’s specificity for queuosine uptake in human cell lines. This precision emphasizes the gene’s evolutionary importance and its potential as a therapeutic target.

Vincent Kelly, professor at Trinity College Dublin and joint senior author of the study, emphasized the broader implications of this finding. “Queuosine’s influence extends to crucial physiological domains such as brain function, metabolic control, cancer biology, and stress resilience. Understanding the means by which queuosine navigates from the gut microbiome to every human cell redefines our view of micronutrient biology,” Kelly stated.

This discovery also sheds light on the intricate relationship between the gut microbiota and host cellular machinery. Given that queuosine is produced by gut bacteria and salvaged by host cells, the identification of SLC35F2 provides a molecular link elucidating how microbial metabolites directly influence human gene expression and function.

Cancer researchers, in particular, may find this insight invaluable. Since SLC35F2 has roles in mediating drug uptake, the newfound understanding of its physiological substrate opens pathways to designing therapies that leverage queuosine transport for targeted drug delivery or metabolic modulation in oncology.

The implications for neurological health are profound as well. Queuosine’s role in modifying tRNAs affects neuronal protein synthesis, with downstream effects on memorization and learning processes. Therapeutic avenues could emerge from modulating SLC35F2 activity or queuosine availability to combat neurodegenerative disorders or cognitive decline.

Funding for this extensive investigation was sourced from leading international health organizations, including the National Institutes of Health (NIH) in the United States, Research Ireland (formerly Science Foundation Ireland), and Health and Social Care in Northern Ireland. Such global collaboration underscores the universal relevance of queuosine biology and the importance of transnational scientific partnerships.

The research brings together an impressive array of institutions beyond the co-leading universities, involving San Diego State University and the Ohio State University alongside Irish academic centers. This synergy exemplifies the power of international cooperation to solve complex biological puzzles.

This seminal work concludes an era of speculation about queuosine transport and opens the floodgates for future research into its physiological roles and therapeutic potential. Researchers anticipate that uncovering the molecular underpinnings of queuosine uptake will catalyze new studies exploring diet, microbiome interactions, and gene regulation with unprecedented clarity.

In summary, the identification of SLC35F2 as the high-specificity transporter of queuosine marks a milestone in molecular biology. It connects nutrition, microbiome science, genetics, and medicine, promising not only to deepen scientific knowledge but also to inspire novel medical interventions aimed at harnessing the untapped potential of micronutrients in promoting human health.

Subject of Research: Identification of the gene SLC35F2 as the specific transporter for the micronutrients queuine and queuosine and its implications in human health.

Article Title: The oncogene SLC35F2 is a high-specificity transporter for the micronutrients queuine and queuosine

News Publication Date: 17-Jun-2025

Web References:
https://www.pnas.org/doi/10.1073/pnas.2425364122
http://dx.doi.org/10.1073/pnas.2425364122

Keywords: Gut microbiota, Bacterial DNA, Queuosine, SLC35F2, micronutrient transport, transfer RNA modification, gene translation, cancer suppression, brain function, microbiome, oncology, metabolism

Queuosine is a unique and elusive molecule classified as a vitamin-like micronutrient. First isolated in the 1970s, it remains one of the most mysterious compounds in human biology, in part because humans lack the biosynthetic machinery to produce it endogenously. Instead, queuosine is acquired exclusively through dietary sources and the metabolic activities of the gut microbiota. Despite being indispensable for various physiological processes, the complexities of how queuosine enters and functions within human cells have largely eluded scientific scrutiny until now.

The recent study, published in the prestigious journal Proceedings of the National Academy of Sciences (PNAS), unveils that the human gene SLC35F2 encodes the key transporter protein responsible for the cellular import of queuosine. This transporter facilitates the assimilation of queuosine into cells, enabling it to perform its critical role as a post-transcriptional modification to transfer RNA (tRNA). The modification fine-tunes the cellular translation machinery, ensuring genetic information is accurately decoded into functional proteins. Errors in this process are associated with numerous diseases, highlighting the importance of understanding the pathways that govern queuosine availability.

Professor Vincent Kelly from Trinity College Dublin, senior author of the study, emphasized the transformative nature of this discovery. “For years, we knew queuosine played essential roles in brain health, metabolic regulation, cancer biology, and stress responses," he explained. “Yet, how this molecule journeyed from the gut environment, where it is sourced, to the billions of cells in the human body remained a mystery. Identifying SLC35F2 as the queuosine transporter bridges this knowledge gap and opens vast research opportunities.”

Until now, the inability to pinpoint how queuosine crosses cell membranes had hampered efforts to unravel its full biological significance. The identification of SLC35F2 as a conserved transporter demonstrates an ancient, evolutionarily preserved mechanism present in organisms ranging from simple unicellular life forms to humans. This evolutionary conservation underscores queuosine’s foundational role across diverse life forms and signals potential broader biological implications beyond what was previously envisioned.

Leading the investigations from the University of Florida, Professor Valérie de Crécy-Lagard conveyed the anticipation that this breakthrough engenders within the scientific community. “Scientists have long suspected the presence of a queuosine transporter,” she stated. “We have pursued this target extensively, understanding that queuosine influences how the microbiome and diet intertwine with gene expression. This discovery fundamentally redefines our concept of nutrient-gene interactions.”

Mechanistically, queuosine’s integration into tRNA molecules enhances the fidelity and efficiency of protein synthesis, a cellular process crucial for maintaining homeostasis and responding to environmental stimuli. Aberrations in tRNA modification patterns, including queuosine deficiency, are implicated in cancer progression, neurological disorders, and metabolic syndromes. Thus, elucidating the molecular machinery behind queuosine transport has immediate relevance to developing novel diagnostic and therapeutic approaches.

Compellingly, the SLC35F2 gene had been previously examined in the context of viral entry and chemotherapeutic drug uptake, yet its physiological role in nutrient transport remained undefined. This newfound function reveals a dual relevance of the gene in both health and disease conditions. Researchers are now poised to investigate how modulation of SLC35F2 activity might influence susceptibility to diseases or responsiveness to treatments, especially in oncology and neurology.

The intersection of microbiota-derived nutrients and host cellular machinery epitomized by queuosine also highlights the broader impact of diet and microbial ecology on human biology. This study exemplifies the intricate symbiosis between humans and their microbiome, where microbial metabolites act as essential cofactors in fundamental cellular processes. Future research will likely delve into how variations in gut microbial populations affect queuosine availability and consequently human health.

The therapeutic potential borne out of this research is substantial. By targeting the queuosine transport pathway, it may be possible to engineer interventions that amplify its beneficial effects or mitigate pathological processes linked to its deficiency. For instance, enhancing queuosine uptake in neurons might bolster cognitive function or delay neurodegenerative decline, while manipulating its role in cancer cells could improve therapeutic outcomes.

Furthermore, the discovery encourages a reassessment of dietary guidelines and nutritional supplementation strategies. Given that queuosine cannot be synthesized by humans, understanding its absorption mechanism empowers nutritionists and clinicians to more precisely tailor diets or develop supplements that optimize queuosine levels, potentially fortifying brain health and immune resilience.

In summary, the identification of SLC35F2 as the transporter responsible for queuosine uptake is a landmark achievement in molecular and nutritional sciences. This advancement bridges a critical divide in our understanding of micronutrient biology, from gut symbionts to cellular function, and paves the way for innovative research and therapy development. As scientific exploration continues, the small but mighty queuosine molecule may emerge as a key player in governing human health and disease, driven by the newly revealed molecular gateway that ushers it into our cells.

Subject of Research: Queuosine nutrient uptake and tRNA modification in human cells

Article Title: Identification of SLC35F2 as the human queuosine transporter facilitating tRNA modification

News Publication Date: 2024

Web References:
10.1073/pnas.2425364122

References:
Proceedings of the National Academy of Sciences (PNAS), 2024

Keywords: Queuosine, tRNA modification, micronutrient transport, SLC35F2, gene expression, protein synthesis, microbiome, cancer suppression, brain function, molecular biology, nutrient-gene interaction